Telomere length as a predictor of therapy response and survival in patients diagnosed with ovarian carcinoma.

Ovarian cancer Shelterin Telomerase Telomere length Therapy response

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
15 Jul 2024
Historique:
received: 18 07 2023
revised: 14 06 2024
accepted: 23 06 2024
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 25 7 2024
Statut: epublish

Résumé

Impaired telomere length (TL) maintenance in ovarian tissue may play a pivotal role in the onset of epithelial ovarian cancer (OvC). TL in either target or surrogate tissue (blood) is currently being investigated for use as a predictor in anti-OvC therapy or as a biomarker of the disease progression, respectively. There is currently an urgent need for an appropriate approach to chemotherapy response prediction. We performed a monochrome multiplex qPCR measurement of TL in peripheral blood leukocytes (PBL) and tumor tissues of 209 OvC patients. The methylation status and gene expression of the shelterin complex and telomerase catalytic subunit (

Identifiants

DOI: 10.1016/j.heliyon.2024.e33525 PMID: 39050459 PMC: PMC11268197
pubmed: 39050459
doi: 10.1016/j.heliyon.2024.e33525
pii: S2405-8440(24)09556-2
pmc: PMC11268197
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e33525

Informations de copyright

© 2024 The Authors. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Mod Pathol. 2018 Jul;31(7):1107-1115
pubmed: 29449679
Aging (Albany NY). 2015 Dec;7(12):1066-76
pubmed: 26638179
Int J Cancer. 2016 Dec 15;139(12):2655-2670
pubmed: 27459707
Oncogene. 1999 Feb 4;18(5):1219-26
pubmed: 10022128
Cell Res. 2017 Dec;27(12):1485-1502
pubmed: 29160297
Nat Rev Cancer. 2008 Mar;8(3):167-79
pubmed: 18256617
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
J Pathol. 2014 Mar;232(4):473-81
pubmed: 24338723
Front Oncol. 2021 Sep 23;11:737776
pubmed: 34631571
Ann Med. 2001 Mar;33(2):123-9
pubmed: 11327115
Eur J Obstet Gynecol Reprod Biol. 2007 Feb;130(2):249-57
pubmed: 16519988
Oncol Rep. 2020 Sep;44(3):927-938
pubmed: 32705217
Mod Pathol. 2015 Feb;28(2):303-11
pubmed: 25081752
Genome Biol. 2014;15(8):435
pubmed: 25146004
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
PLoS One. 2013 Nov 19;8(11):e81034
pubmed: 24260532
Epigenomics. 2009 Oct;1(1):177-200
pubmed: 22122642
Sci Rep. 2016 Mar 14;6:22886
pubmed: 26971878
Biomed Res Int. 2018 Feb 6;2018:7184253
pubmed: 29546066
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592
pubmed: 36300620
Genes Dev. 2010 Mar 15;24(6):613-22
pubmed: 20231318
Nat Genet. 2013 Apr;45(4):371-84, 384e1-2
pubmed: 23535731
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Mutagenesis. 2020 Jul 11;35(3):261-271
pubmed: 32083302
Gynecol Oncol. 2004 May;93(2):407-16
pubmed: 15099954
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
J Exp Bot. 2009;60(2):487-93
pubmed: 19264760
Genome Biol. 2016 Oct 7;17(1):208
pubmed: 27717381
Br J Cancer. 2019 Aug;121(4):344-350
pubmed: 31312029
FEBS Lett. 2018 Jun;592(12):2023-2031
pubmed: 29749098
Nat Rev Genet. 2010 May;11(5):319-30
pubmed: 20351727
Biostatistics. 2017 Apr 1;18(2):275-294
pubmed: 27756721
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2603-6
pubmed: 25159293
Nat Commun. 2018 Jul 26;9(1):2923
pubmed: 30050129
Cancers (Basel). 2020 Feb 28;12(3):
pubmed: 32121056
BMC Bioinformatics. 2010 Nov 30;11:587
pubmed: 21118553
Mol Cell. 2016 Jan 21;61(2):236-46
pubmed: 26778124
Cells. 2021 Apr 10;10(4):
pubmed: 33920284
Mod Pathol. 2011 Aug;24(8):1139-45
pubmed: 21499239
Cells. 2019 May 04;8(5):
pubmed: 31060240
Nat Rev Mol Cell Biol. 2017 Mar;18(3):175-186
pubmed: 28096526
Genetics. 2023 May 4;224(1):
pubmed: 36866529
Dalton Trans. 2023 Aug 8;52(31):10942-10950
pubmed: 37490033
Bioinformatics. 2017 Feb 15;33(4):558-560
pubmed: 28035024
Cancer Res. 2020 Apr 15;80(8):1748-1761
pubmed: 32054768
Int J Gynecol Cancer. 2011 May;21(4):771-5
pubmed: 21543939
Bioinformatics. 2015 Feb 15;31(4):608-9
pubmed: 25677125
Immunol Lett. 2024 Feb;265:7-15
pubmed: 38122906
Genome Biol. 2012 Jun 15;13(6):R44
pubmed: 22703947
Front Oncol. 2022 Dec 02;12:1016958
pubmed: 36531044
J Ovarian Res. 2020 Sep 23;13(1):115
pubmed: 32967712
Mutagenesis. 2020 Dec 31;35(6):491-497
pubmed: 33367858
Annu Rev Genet. 2018 Nov 23;52:223-247
pubmed: 30208292
Oncogene. 2018 Apr;37(17):2285-2301
pubmed: 29398710
Epigenomics. 2012 Jun;4(3):325-41
pubmed: 22690668

Auteurs

Kristyna Tomasova (K)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/77, 32300, Pilsen, Czech Republic.

Karolina Seborova (K)

Toxicogenomics Unit, National Institute of Public Health, Srobarova 48, 100 42, Prague, Czech Republic.
Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, 323 00, Pilsen, Czech Republic.

Michal Kroupa (M)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/77, 32300, Pilsen, Czech Republic.

Josef Horak (J)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Third Faculty of Medicine, Charles University, Ruska 87, 100 00, Prague, Czech Republic.

Miriam Kavec (M)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic.

Ludmila Vodickova (L)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/77, 32300, Pilsen, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.

Lukas Rob (L)

Department of Gynecology and Obstetrics, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.

Martin Hruda (M)

Department of Gynecology and Obstetrics, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.

Marcela Mrhalova (M)

Department of Pathology and Molecular Medicine, Second Faculty of Medicine and Motol University Hospital, Charles University, Prague, Czech Republic.

Alena Bartakova (A)

Department of Gynecology and Obstetrics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.

Jiri Bouda (J)

Department of Gynecology and Obstetrics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.

Thomas Fleischer (T)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.

Vessela N Kristensen (VN)

Department of Medical Genetics, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

Pavel Vodicka (P)

Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic.
Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/77, 32300, Pilsen, Czech Republic.
Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic.

Radka Vaclavikova (R)

Toxicogenomics Unit, National Institute of Public Health, Srobarova 48, 100 42, Prague, Czech Republic.
Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655/76, 323 00, Pilsen, Czech Republic.

Classifications MeSH